Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years?
Overview
Affiliations
The evolution of locoregional therapies in the last decade has been refined with improved patient selection and a development of a more personalized approach. In doing so, there has been associated improved outcomes and less toxicity. With the rapidly changing landscape of systemic therapy, the role of locoregional therapies alone or in combination for downstaging and curative intent will continue to evolve.
Lang D, Agarwal R, Brown S, Borgmann A, Lockney N, Goff L Adv Oncol. 2024; 4(1):247-262.
PMID: 38882260 PMC: 11178262. DOI: 10.1016/j.yao.2024.02.002.
Jeng L, Wang J, Teng C J Cancer. 2024; 15(2):484-493.
PMID: 38169551 PMC: 10758026. DOI: 10.7150/jca.90128.
Li X, Wang Y, Ye X, Liang P Front Mol Biosci. 2021; 8:635243.
PMID: 33928118 PMC: 8076864. DOI: 10.3389/fmolb.2021.635243.